MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

Inclusion Criteria

• •Pathologically confirmed (histologic or cytologic), locally advanced, adenocarcinoma of the pancreas; patients must have unresectable disease based on institutional standardized criteria of unresectability or medical inoperability.
• •Participants with and without regional adenopathy are eligible.
• •No distant metastases, based upon the following minimum diagnostic workup:
• •History/physical examination, including collection of weight and vital signs, within 28 days prior to study entry;
• •Abdominal/pelvic CT scan with IV contrast within 21 days prior to study entry;
• •Chest CT scan, or X-ray within 21 days prior to study entry.
• •Abdominal/pelvic MR prior to radiation with perfusion and diffusion- weighted sequences and MR and CT sim for radiation planning Pet scan within 21 days prior to study entry, Functional renal study.
• •Zubrod performance status 0-1 within 1 week of study entry.
• •Age ≥ 18.
• •Hematology and cancer antigen (CA) 19-9 / carcinoembryonic antigen (CEA) within 14 days prior to study entry, as follows.
• •Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3;
• •Platelets ≥ 100,000 cells/mm\^3;
• •Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.);
• •Serum creatinine ≤ 1.5 mg/dl;
• •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 3 x upper limit of normal (ULN);
• •Total bilirubin \< 3.0 mg/dL;
• •Alkaline phosphatase \< 3 x ULN;
• •Fasting blood glucose \< 160 mg/dl.
• •Negative serum pregnancy test (if applicable) within 14 days prior to study entry.
• •Ability to swallow oral medications.
• •Participants must have had at least 4 months of prior systemic chemotherapy.
• •Participants must provide study specific informed consent prior to study entry.
• •Women of childbearing potential and male participants who are sexually active must practice adequate contraception.